The gamble paid off, as Merck was able to file a new-drug application six weeks before Novartis.

FORBES: Health

After completion of more pre-clinical studies, Short hopes to file Diversa's first investigational new drug application sometime next year.

FORBES: Taking Aim At Anthrax